Rare Pediatric Disease
Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher
Anika Sharma
Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...
Sarepta Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $102 Million to Boost Research and Development
SG Tylor
Source – Sarepta Therapeutics On July 5, 2023, Sarepta Therapeutics, a leading company in precision genetic medicine for rare diseases, ...
